Abstract | PURPOSE: PATIENTS AND METHODS: Patients with hematologic malignancies underwent autologous or allogeneic BMT or SCT and received rIL-2 by continuous intravenous infusion a median of 33 to 56 days later. In all trials, the rIL-2 regimen consisted of a moderate induction dose for 4 to 5 days in the hospital, 4 to 6 days of rest, and a low maintenance dose for 10 days in the outpatient setting. A phase I trial of Roche rIL-2 after autoBMT, a feasibility trial of autologous lymphokine-activated killer cells with rIL-2, and another phase I/II trial of Chiron rIL-2 after autoBMT were performed. A similar phase I trial of IL-2 after alloBMT was also performed in children with acute leukemia beyond first complete remission. RESULTS: An rIL-2 regimen has been identified that can be tolerated early after transplantation. Administration of this rIL-2 regimen induces marked increases in CD3+CD8+ T lymphocytes and CD3-CD56+ natural killer cells and enhances their antitumor cytolytic activity. Encouraging but somewhat inconsistent clinical outcomes were noted in phase I/II trials in patients with lymphoma and acute myeloid leukemia. CONCLUSIONS: The results of phase I/II trials are sufficiently encouraging to justify prospectively randomized phase III trials to determine whether rIL-2 after autologous SCT will reduce the rate of posttransplantation relapse and improve survival in patients with advanced hematologic malignancies.
|
Authors | A Fefer, N Robinson, M C Benyunes, W I Bensinger, O Press, J A Thompson, C Lindgren |
Journal | The cancer journal from Scientific American
(Cancer J Sci Am)
Vol. 3 Suppl 1
Pg. S48-53
(Dec 1997)
ISSN: 1081-4442 [Print] United States |
PMID | 9457394
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Interleukin-2
- Recombinant Proteins
|
Topics |
- Adolescent
- Adult
- Bone Marrow Transplantation
- Child
- Child, Preschool
- Hematologic Neoplasms
(mortality, therapy)
- Hematopoietic Stem Cell Transplantation
- Humans
- Immunotherapy
- Infant
- Injections, Intravenous
- Interleukin-2
(administration & dosage, therapeutic use)
- Recombinant Proteins
(therapeutic use)
- Survival Rate
- Treatment Outcome
|